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a b s t r a c t
Amongst the human papillomaviruses (HPVs), the genus Alphapapillomavirus contains HPV types that are
uniquely pathogenic. They can be classiﬁed into species and types based on genetic distances between
viral genomes. Current circulating infectious HPVs constitute a set of viral genomes that have evolved
with the rapid expansion of the human population. Viral variants were initially identiﬁed through
restriction enzyme polymorphisms and more recently through sequence determination of viral
fragments. Using partial sequence information, the history of variants, and the association of HPV
variants with disease will be discussed with the main focus on the recent utilization of full genome
sequence information for variant analyses. The use of multiple sequence alignments of complete viral
genomes and phylogenetic analyses have begun to deﬁne variant lineages and sublineages using
empirically deﬁned differences of 1.0–10.0% and 0.5–1.0%, respectively. These studies provide the basis
to deﬁne the genetics of HPV pathogenesis.
& 2013 Elsevier Inc. All rights reserved.
Introduction and background
Papillomaviruses are small circular double-stranded DNA viruses.
They are highly species speciﬁc and preferentially infect cutaneous or
mucocutaneous epithelium. Papillomavirus genomes have been iso-
lated and characterized from reptiles (Herbst et al., 2009), birds (Terai
et al., 2002), marsupials (Bennett et al., 2010) and multiple other
mammalian species (for recent review see Bernard et al. (2010))
suggesting an evolutionary history spanning more than 300 million
years (Herbst et al., 2009). Papillomaviruses replicate their genomes
using the host enzymatic machinery, ensuring a high degree of proof
reading with low mutation rates (Rector et al., 2007). As their
genomes have evolved, mutations, insertions/deletions (indels) and
rearrangements have been selected and/or ﬁxed through host isola-
tion into discrete entities (called types), with the intermediary
genomes generally lost (Bernard et al., 2006; Gottschling et al.,
2007). More recent evolutionary events are responsible for the large
heterogeneity of related viral variants detected in the modern era.
Papillomavirus evolution has been predominantly asexual,
although extremely rare recombination events cannot be excluded.
This implies that multiple mutations/variations occurring in papil-
lomavirus genomes are not related to genetic distance as in
recombining genomes, i.e., linkage disequilibrium, but to sequential
accumulation of genetic changes. This process of speciation has
been termed lineage ﬁxation (Chen et al., 2005). That is, groups of
single nucleotide polymorphisms and/or insertions/deletions
(indels) tend to become ﬁxed within viral lineages. Over time, the
quantity of these lineage-deﬁning variations increases eventually
leading to speciation (entities referred to as types). For papilloma-
viruses this has been deﬁned when approximately 10% or more of
the nucleotide positions differ between 2 genomes that share a
most recent common ancestor; this takes millions of years (Chen
et al., 2009; Rector et al., 2007).
A distinct human papillomavirus (HPV) “type” is established
and curated when the DNA sequence of the L1 open reading frame
(ORF) of the cloned viral genome differs from that of any other
characterized type by at least 10% (Bernard et al., 2010; de Villiers
et al., 2004). Within the PV research community, isolates of the
same HPV type are referred to as variants or subtypes when
the nucleotide sequences of the L1 ORF differ by less than 10%. The
criterion for HPV types has proven extremely stable and useful for
basic researchers, clinicians, epidemiologists and immunologists.
Over 160 HPV types have been fully characterized (see 〈http://
www.hpvcenter.se/html/refclones.html〉); approximately 60 of these
are predominantly detected in mucosal epithelia and sort to the
genus Alphapapillomavirus (alpha-PV) (Bernard et al., 2010; de Villiers
et al., 2004). Human alpha-PV infections are involved in the devel-
opment of both benign and malignant disease, e.g., condylomata
acuminatum/respiratory papillomatosis and cervical/anal/head and
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neck cancers, respectively. Cervical cancer is the most common
gynecologic malignancy and one of the leading causes of cancer
mortality in women worldwide (Jemal et al., 2011). Most oncogenic
or high-risk (HR) types associated with invasive cervical cancer
(Li et al., 2011; Munoz et al., 2003; Smith et al., 2007) are clustered
in one clade of the alpha-HPVs that contains species groups alpha-5,
alpha-6, alpha-7 and alpha-9 (Burk et al., 2009; Schiffman et al.,
2005) and account for 90% of all cervical cancers worldwide
(Li et al., 2011; Smith et al., 2007). Despite phylogenetic relatedness,
HPV variants can differ in pathogenicity (Berumen et al., 2001; Burk
et al., 2003; Chan et al., 2013; Cornet et al., 2013b; Giannoudis and
Herrington, 2001; Hecht et al., 1995; Sabol et al., 2012; Schiffman
et al., 2010; Villa et al., 2000; Xi et al., 2007). Because of their medical
importance, the predominant research focus on papillomaviruses is
their association with pathologic and oncogenic lesions. Thus, this
review will focus exclusively on human papillomaviruses and pre-
dominantly on the HPVs within the genus Alphapapillomavirus.
In this review, we update knowledge of variant lineages and
sublineages using currently available complete genome sequences
of human Alphapapillomavirus from species groups: alpha-3
(HPV61), alpha-5 (HPV26, 51, 69 and 82), alpha-6 (HPV30, 53,
56, 66), alpha-7 (HPV18, 39, 45, 59, 68, 70, 85 and 97), alpha-9
(HPV16, 31, 33, 35, 52, 58 and 67), alpha-10 (HPV6 and 11), alpha-
11 (HPV34 and 73) and alpha-13 (HPV54). We summarize the
rationale for the grouping of related HPV types and highlight
HPV16 lineages as an example of the increased complexity in a
dichotomized classiﬁcation into European and non-European
groups by reviewing the use of an alphanumeric nomenclature.
The establishment of a coherent classiﬁcation and nomenclature
system for HPV variant lineages will facilitate comparisons
amongst studies that directly determine HPV sequences, especially
as next-generation sequencing of PCR products and complete
sample DNA (metagenomics) is rapidly being applied in new
studies (Barzon et al., 2011; Conway et al., 2012; Ekstrom et al.,
2011; Mokili et al., 2013). Moreover, speciﬁc variants occur on
lineages that are stable and have correlated changes and diagnos-
tic polymorphisms throughout the genome that can be used by all
investigators (Alizon et al., 2011; Chen et al., 2005). Without a
system for naming variant lineages, investigators have had to rely
on referring to speciﬁc changes at nucleotide positions.
Historical perspective and previous reviews of HPV variants
This review builds upon the pioneering work of early investi-
gators in the ﬁeld that appreciated the signiﬁcance of studying
HPV variants. The earliest work in the ﬁeld predated PCR and
relied upon restriction enzyme digestion polymorphisms and/or
Southern blot hybridization to recognize related viral variants
(de Villiers et al., 1981; Mounts et al., 1982). Previous reviews of
viral variants can be found from the era when sequencing DNA
was cumbersome, time consuming and technically challenging
(Bernard, 1994; Bernard et al., 1994). The lab of Bernard was the
ﬁrst to recognize the association of HPV16 (Ho et al., 1993) and
HPV18 (Ong et al., 1993) viral variants with human population
migrations and continent of origin (see Bernard (1994)) for review
of this topic). The lab of CM Wheeler provided some of the early
evidence for the intratype variation of HPV types associated with
cervical neoplasia and HPV16 and HPV18 heterogeneity (Arias-
Pulido et al., 2005; Stewart et al., 1996; Yamada et al., 1997, 1995).
With the demonstration of an association of HPV16 variants and
cervical cancer (Berumen et al., 2001; Cornet et al., 2013b;
Hildesheim et al., 2001; Sichero et al., 2007; Xi et al., 2006), many
of the studies on variants explored this aspect of the biology of
variants as described in a number of excellent reviews (Bernard
et al., 2006; Giannoudis and Herrington, 2001; Hildesheim and
Wang, 2002; Lizano et al., 2009; Sichero and Villa, 2006). This
current review focuses predominantly on the study of alpha-HPV
variants using complete genome analyses.
The study of HPV variants from other genera provided evidence
for signiﬁcant intratype variation of HPV5 and HPV8 from indivi-
duals with epidermodysplasia verruciformis (Deau et al., 1993,
1991). In fact, the intratype heterogeneity of HPVs from the genera
Betapapillomavirus and Gammapapillomavirus has remained basi-
cally unexplored, and there is currently a signiﬁcant effort to
characterize novel types from these genera (Bottalico et al., 2011;
Kohler et al., 2011; Li et al., 2012). With implementation of Next-
Gen sequencing (Barzon et al., 2011; Ekstrom et al., 2011), it is
anticipated that there will be rapid advances in studying these
genome variants (Bernard, 2013), particularly if associated with
pathologic lesions.
Although the co-evolution of human populations and HPV16
and HPV18 variants is well supported, the geographic associations
for variants of other types remains unresolved (Calleja-Macias
et al., 2004, 2005; Chan et al., 1997; Heinzel et al., 1995; Matos
et al., 2013; Prado et al., 2005). Global studies of HPV variant
lineages from worldwide populations are needed to better under-
stand the relationship between HPV and the recent and past
evolution and dispersion of their human hosts.
HPV variants and cervical cancer pathogenesis
The natural history of HPV and subsequent development of
cervical cancer follows a set of stages from sexual exposure to an
oncogenic HPV (Bouvard et al., 2009), persistence of infection,
development of a precancerous lesion and progression of the
precancerous lesion to invasive disease (for recent review see
Schiffman and Wentzensen (2013)). Each stage of a pernicious
papillomavirus infection leading to cancer (Burk, 1999) may be
inﬂuenced by both the host and viral genome variations and
environmental factors (Hildesheim and Wang, 2002; Wheeler,
2008). Since the outcome of cervical cancer for any speciﬁc HPV
exposure is extremely rare, most studies have used case-control
designs to investigate the association of speciﬁc variants with
precancer and cervix cancer. Histologic diagnosis is the end point
of choice, although many studies have used cytologic outcomes.
The most robust histologic “biomarker” of precancer is cervical
intraepithelial neoplasia grade 3 lesions (CIN3) (Luhn et al., 2013),
nevertheless studies also utilize CIN2 to enhance power by
forming a high-grade class. Thus, if we only consider oncogenic
HPV types, the contribution of viral variants to cancer develop-
ment could be related to (1) acquisition of infection given
exposure (differences in infectivity), (2) long-term persistence
(e.g., greater than 1 or 2 years and could reﬂect viral differences
in immune clearance or other properties), (3) development of pre-
cancer usually given persistence (differences in viral dysregulation
of cellular differentiation and/or accumulation of somatic cellular
changes in the premalignant or stromal cells) and lastly, (4) inva-
sion of HPV containing cells. It is assumed that most invasive
cervix cancer goes through all stages, however there are signiﬁcant
differences between the more common squamous cell carcinoma
and the rarer adenocarcinoma of the cervix (Kim et al., 2013;
Schiffman et al., 2007; Schiffman and Wentzensen, 2013).
Analysis of the pathogenic affects of HPV variants for this
review encompassed evaluation of over 50 manuscripts spanning
nearly 20 years. The topic turned out to be extremely complicated
because of the complexity of the interaction of the virus with
differences in host genetics (de Araujo Souza et al., 2009;
Hildesheim and Wang, 2002; Xi et al., 2006) and prevalence of
circulating HPV variants in different populations and/or geo-
graphic regions. In addition, description or characterization of
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Table 1
Representative genomes for viral variant lineages and sublineages.
Species Type Lineage Sublineage Variant genome ID GenBank accession no. Other names*
Alpha-9 HPV16 A A1 Ref K02718 European (E)
A2 W0122 AF536179 European (E)
A3 AS411 HQ644236 E
A4 W0724 AF534061 Asian, E(As)
B B1 W0236 AF536180 African-1, Afr1a
B2 Z109 HQ644298 African-1, Afr1b
C R460 AF472509 African-2, Afr2a
D D1 QV00512 HQ644257 North American (NA)1
D2 QV15321 AY686579 Asian–American (AA)2
D3 QV00995 AF402678 Asian–American (AA)1
HPV31 A A1 Ref J04353
A2 IN221709 HQ537675
B B1 QV03876 HQ537676
B2 QV17700 HQ537680
C C1 QV03136 HQ537682
C2 QV14043 HQ537684
C3 QV00693 HQ537685
HPV33 A A1 Ref M12732 A
A2 QV34060 HQ537698 B
A3 LZcc12 EU918766
B QV23819 HQ537705 C
C BF375 KF436865
HPV35 A A1 Ref X74477
A2 RW128 HQ537727
HPV52 A A1 Ref X74481
A2 QV15145 HQ537739
B B1 QV03594 HQ537740
B2 IN141070 HQ537743
C C1 QV05867 HQ537744
C2 QV00615 HQ537746
D QV02575 HQ537748
HPV58 A A1 Ref D90400
A2 QV15606 HQ537752
A3 QV00961 HQ537758
B B1 BF134 HQ537762
B2 RW937 HQ537764
C QV13816 HQ537774
D D1 QV03841 HQ537768
D2 RW697 HQ537770
HPV67 A A1 Ref D21208
A2 QV22701 HQ537780
B QV25738 HQ537783
Alpha-7 HPV18 A A1 Ref AY262282 AsAi, AA, E1
A2 Qv16306 EF202146 AsAi, AA, E1
A3 Qv15586 EF202147 E, E2
A4 Qv02876 EF202151 E, E2
A5 CU11 GQ180787 E
B B1 Qv04924 EF202155 Af, Af1
B2 BF172 KC470225 Af
B3 Qv17199 EF202152 Af, Af2
C Qv39775 KC470229 Af
HPV39 A A1 Ref M62849
A2 Qv21219 KC470239
B RW72 KC470247
HPV45 A A1 Ref X74479
A2 Qv27565 EF202157
A3 BF134 KC470256
B B1 Qv00550 EF202161
B2 Qv25000 EF202164
HPV59 A A1 Ref X77858
A2 Qv25652 KC470261
A3 Qv23880 KC470263
B Qv25808 KC470264
HPV68 A A1 Ref X67161 A
A2 Qv01017 KC470269 A
B Qv18016 KC470270 A
C C1 ME180 FR751039 B
C2 Qv33015 KC470274 B
D D1 Qv00677 KC470275 B
D2 Qv30285 KC470276 B
E Qv17725 KC470277 B
F F1 Qv25395 KC470279 B
F2 Rw826 KC470281
HPV70 A Ref U21941
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the variants was not always simple to convert to a “categorical”
description, such as has been previously designated or summar-
ized in this review (see Table 1 and Figs. 1–5). No studies on
relative infectivity were identiﬁed, thus point 1 above has not
been evaluated for different variants. A summary of the current
data is presented below.
Table 1 (continued )
Species Type Lineage Sublineage Variant genome ID GenBank accession no. Other names*
B Qv05102 KC470287
HPV85 A Ref AF131950
HPV97 A Ref EF202168
Alpha-5 HPV26 A Ref X74472
HPV51 A A1 Ref M62877
A2 QV00891 KF436870
A3 INJP06405 KF436873
A4 QV09427 KF436875
B B1 QV10565 KF436883
B2 BF366 KF436886
HPV69 A A1 Ref AB027020 A
A2 QV29573 KF436859 A
A3 QV35103 KF436861 A
A4 QV31811 KF436863 B
HPV82 A A1 Ref AB027021
A2 QV34571 KF436787
A3 QV28313 KF436793
B B1 RW17 KF436794
B2 P5_860 KF444055
C C1 IS39/AE2 AF293961
C2 RW606 KF436800
C3 RW74 KF436801
C4 RW15 KF436802
C5 QV28248 KF436803
Alpha-6 HPV30 A A1 Ref X74474
A2 QV00510 KF436842
A3 RW060 KF436844
B QV31356 KF436850
HPV53 A Ref X74482 A
B RW866 KF436818
C QV28044 EF546477 B
D D1 QV31688 EF546482 B
D2 QV28877 KF436823 B
D3 TJ43 GQ472849
D4 QV22707 EF546479 B
HPV56 A A1 Ref X74483 A
A2 QV22608 EF177179 B
B QV26762 EF177176 C
HPV66 A Ref U31794
B B1 QV25111 EF177188
B2 QV25260 EF177187
Alpha-11 HPV34 A A1 Ref X74476
A2 QV24615 KF436808
B QV12026 KF436810
C C1 QV34920 KF436812
C2 QV29446 KF436816
HPV73 A A1 Ref X94165
A2 QV23185 KF436829
B QV00749 KF436834
Alpha-10 HPV6 A Ref X00203
B B1 CAC306 FR751337
B2 CAC301 FR751328
B3 6a L41216
HPV11 A A1 Ref M14119
A2 CAC86 FN907962
Alpha-13 HPV54 A Ref U37488
B AE9 AF436129
C QV18028 KF436894
Alpha-3 HPV61 A A1 Ref U31793
A2 RW062 KF436853
B QV02384 KF436856
C RW940 KF436858
The DNA sequences of complete HPV genomes used in this report are listed and represent a “reference genome” for a given lineage or sublineage.
* Other common names for HPV16 are shown and can be found in the following references (Cornet et al., 2012; Ho et al., 1993; Smith et al., 2011; Yamada et al., 1995), as
can other names for HPV18 (Arias-Pulido et al., 2005; Chen et al., 2009; Ong et al., 1993), previous assignments for lineages for HPV33/53/56/68/69 variants analyzed in
Schiffman et al. (2010) that have changed are also listed above.
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HPV16 variants and cervical pathogenesis
There is compelling data that HPV16 variants inﬂuence persis-
tence, progression to precancer, development of cancer and
histologic type of cervix cancer. Most studies implicate the non-
European (NE) lineages (B/C/D, see Fig. 1) as being more patho-
genic in comparison to isolates from the European (E) lineage (A).
Persistence
The magnitude of the effect (NE vs. E) is approximately 2-fold
(Schiffman et al., 2010; Villa et al., 2000); although this biologic
affect can be modiﬁed by host genetic makeup (Xi et al., 2006).
Amongst European populations with predominantly HPV16 iso-
lates of the A lineage, variation at HPV16 EUR-350T vs. 350G,
imparted an approximately 2 fold risk of persistence (Cornet et al.,
2013a; Gheit et al., 2011).
Precancer
Consistent results implicate the NE lineages compared to E
isolates, with a 2–4 fold increase for cervical neoplasia in general
and CIN3, speciﬁcally, in many studies (Hildesheim et al., 2001;
Schiffman et al., 2010; Sichero et al., 2007; Villa et al., 2000; Xi et al.,
2007; Zuna et al., 2009). Complexities of differences in HPV16 variant
distributions in speciﬁc populations have indicated that in Taiwan,
the E(As) or A4 lineage imparts a 10-fold risk for CIN3þ compared to
the E lineage (A1). This study demonstrated that within a speciﬁc
lineage there can be deﬁnable viral genetic markers, as had been
suggested for the AA (D) lineage (Smith et al., 2011).
Cancer and histologic subtype
There is a strong evidence that HPV16 NE variants have
elevated risks for cancer, although much of the affect is related
to the increased risk for the AA (D) lineage (Berumen et al., 2001;
Burk et al., 2003; Zuna et al., 2009), and there appears to be
geographic complexity (Cornet et al., 2013b). There is also multiple
studies that indicate the HPV16 AA (D) lineage compared to the E
(A) lineage is disproportionately (4–35 fold increased) associated
with adenocarcinoma (AdCa) vs. squamous cell carcinoma (SCC)
(Berumen et al., 2001; Burk et al., 2003; Quint et al., 2010; Zuna
et al., 2011). Nevertheless, a study from Indonesian, Surinamese
Fig. 1. HPV16 variant tree topology and pairwise comparisons of individual complete genomes. A maximum likelihood (ML) tree was inferred from a global alignment of 62
complete genome nucleotide sequences of HPV16 using RAxML HPC v7.2.8 (Stamatakis, 2006). The 62 HPV16 genomes were previously described in Smith et al. (2011).
Distinct variant lineages (i.e., termed A/B/C/D) and sublineages (e.g., termed A1/A2/A3/A4) were classiﬁed according to the topology and nucleotide sequence differences
from 41% to o10%, and 40.5% to o1% ranges, respectively (Bernard et al., 2010; Chen et al., 2011). The p-distance method in MEGA5 (Tamura et al., 2011) was used to
calculate pairwise nucleotide sequence differences for each isolate compared to all other isolates based on the complete genome nucleotide sequences and are shown in the
middle panel, labeled “Complete genome” at the top of the ﬁgure. For comparison, the L1 ORF nucleotide sequence of each isolate was compared to that of all other isolates
and is shown in the right panel, labeled “L1 ORF”. Values for each comparison of a given isolate are connected by lines and the comparison to self is indicated by the 0%
difference point.
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and Dutch cancer cases did not replicate this ﬁnding (De Boer
et al., 2005).
HPV18 variants and cervical pathogenesis
HPV18 is the second most common HPV type associated with
cervix cancer, but it is much less prevalent than HPV16 in the
population limiting study of this interesting oncogenic HPV. In
fact, there is a lack of compelling evidence for HPV18 variants role
in different stages of the pathogenesis.
Persistence
There are conﬂicting studies on whether non-African
(European) A lineage isolates or Af variants (B/C) are associated
with persistence (Schiffman et al., 2010; Sichero et al., 2007).
These analyses could be confounded by genetic make-up of the
host (Xi et al., 2006).
Precancer
There are few studies on precancer, in part, because it is
well established that HPV18-associated precancerous lesions are
infrequently detected compared to HPV18-related cancer (Guan
et al., 2012). At least one study indicates that the European and AsAi
variants are approximately 2-fold risk factors compared to the Af
variants for 2-year cumulative incidence of CIN3 (Xi et al., 2007).
Cancer and histologic subtype
There is no compelling evidence that different HPV18 variants
are associated with risk of cancer (Arias-Pulido et al., 2005).
However, one out of three studies suggests that the AsAi lineage
(A1/A2) is 4-fold more common in AdCa than the E lineage (A3/A4)
(Arias-Pulido et al., 2005; Burk et al., 2003; De Boer et al., 2005).
HPV31 variants and cervical pathogenesis
Two recent studies provide consistent data that HPV31 lineage
C is more persistent that A and/or B (Schiffman et al., 2010; Xi
et al., 2013). Enigmatically, it appears that HPV31 lineages A/B are
more commonly associated with and development of, CIN3
(Schiffman et al., 2010; Xi et al., 2012). In particular, lineage B
was associated with CIN3 compared to lineage C with an aOR of
2.7 (95% CI: 1.2–5.7) (Xi et al., 2012).
Fig. 2. Phylogenetic trees showing representative types and variant lineages/sublineages of alpha-9. A maximum likelihood tree was constructed using RAxML HPC v7.2.8
(Stamatakis, 2006) inferred from the global alignment of complete genome nucleotide sequences using the program MUSCLE (Edgar, 2004) linearized at the ﬁrst ATG of the
E1 ORF. Representative genomes of each lineage and/or sublineage are listed in Table 1, with GenBank accession numbers. The bold part represents groupings of each type.
The length of dashed and solid lines represents distance between isolates, although the number of changes is different for these two lines; the scale is indicated in the upper
left corner of Figs. 2, 4 and 5; it is shown in the upper right corner of Fig. 3.
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HPV52 variants and cervical pathogenesis
At least 2 groups have reported that HPV52 variants are
associated with precancer (Chang et al., 2011; Formentin et al.,
2013; Schiffman et al., 2010). The most convincing association was
reported from a large study in Taiwan that demonstrated variants
from lineage C compared to B were associated with a 7.6 fold risk
(95% CI: 1.3–44) in women with HPV52 as a single infection
(Chang et al., 2011). In contrast, a study from Canada indicated
the A1 lineage was more common in CIN2/3 (OR¼10.5, 95% CI:
1.2–96) (Formentin et al., 2013).
HPV58 variants and cervical pathogenesis
The complexity of HPV58 heterogeneity has complicated com-
piling the few studies that have investigated these variants (Chan
et al., 2013; Chang et al., 2011; Schiffman et al., 2010). A study from
Taiwan reported that in single HPV58 infections, lineage A1
compared to A3 was associated with CIN3þ in a nested case-
control study (OR¼2.4, 95% CI: 0.5–12.1). In contrast, another
study indicated A3 was a risk factor for CIN3þ(OR¼4.4, 95% CI:
1.5–13) (Chan et al., 2013). Lastly, comparison of A vs. B/C/D
suggested the former lineage was associated with persistence
and possibly CIN3þ (Schiffman et al., 2010).
Future studies investigating the association and/or risks of infec-
tion with speciﬁc variants should consider grouping variants by
categorical states, such as lineages or sublineages as the ﬁrst level
of testing hypothesis about natural history or disease states. This
recommendation is based on the fact that most nucleotide changes
within lineages are highly correlated and analysis by lineage takes
this into consideration. However, there are also non-lineage speciﬁc
changes (e.g., SNPs) that should be analyzed independently (Smith
et al., 2011). With implementation of Next-Gen sequencing in large
studies, future work will illuminate the role of variants in the
pathogenesis of cervix cancer. Consideration of population stratiﬁca-
tion and other risk factors will require large collaborative studies.
The era of whole genome analyses
HPV variant classiﬁcation: lineage and sublineage taxons
The parameters for classifying related isolates of a given type
were previously reported using the large dataset for HPV isolates
Fig. 3. Phylogenetic trees showing representative types and variant lineages/sublineages of alpha-7. A maximum likelihood tree was constructed using RAxML HPC v7.2.8
(Stamatakis, 2006) inferred from the global alignment of complete genome nucleotide sequences using the program MUSCLE (Edgar, 2004) linearized at the ﬁrst ATG of the
E1 ORF. Representative genomes of each lineage and/or sublineage are listed in Table 1, with GenBank accession numbers. The bold part represents groupings of each type.
The length of dashed and solid lines represents distance between isolates, although the number of changes is different for these two lines; the scale is indicated in the upper
left corner of Figs. 2, 4 and 5; it is shown in the upper right corner of Fig. 3.
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(HPV16, HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67) from
the alpha-9 species group (Burk et al., 2011; Chen et al., 2011;
Smith et al., 2011). A table of each genome compared to all others
was created from the multiple sequence matrix. The distribution
of percent differences between variants revealed a trimodal
pattern (Fig. S1A). This trimodal distribution of pairwise compar-
isons indicated at least 3 discrete categories of relatedness,
suggesting a natural taxonomy once the underlying relationship
of each distribution was elucidated. To sort out the distinctions
between variants, pairwise comparisons within each variant line-
age (i.e., intra-lineage) or between variant lineages for each of the
seven HPV types (i.e., inter-lineage)(Fig. S1B) were plotted. Pre-
vious examination of phylogenies for each of the alpha-9 types
combined with an approximate cut-off of 1.0% difference between
complete genomes was/is used to deﬁne major variant lineages
based on lineage similarity plots as shown in Fig. 1, middle panel
(Chen et al., 2011, 2005). Each major lineage was/is named using
an alphanumeric, with the “A” clade always containing the
reference genome for each type. The overlap between inter- and
intra-lineage distributions (0.7–0.9%) indicates that a ﬁxed value
cannot simply be used to distinguish variant lineages (Fig. S1B). A
conservative 1.0% difference or more has been used to deﬁne
lineages, with the caveat that no classiﬁcation system can exactly
categorize the process of evolution. Two distributions are
discernable between and within the genome comparisons of
sublineages for each HPV type (Fig. S1C). Differences between
genomes in the 0.5–1% range are designated as sublineages (e.g.,
A1, A2, etc.). These criteria to classify variants of HPV types from
Alphapapillomavirus were based on available complete genomes in
PubMed as part of an ongoing project to decipher HPV viral
evolution and oncogenicity (Burk et al., 2009).
Subtypes
The use of the term “subtype”, although commonly used, at one
time meant a difference in restriction digestion pattern of a
papillomavirus (Mounts et al., 1982), with a current deﬁnition of
genomes that are 2% to o10% different in their L1 ORFs (Bernard
et al., 2010; de Villiers et al., 2004). Because of the large continuum
of differences between existing and potential subtypes, we favor
the use of the term variants to include subtypes. The rationale for
the use of complete genome (CG) sequences to deﬁne viral
lineages instead of a speciﬁc region is well illustrated when
comparing the L1 ORF and CG sequence differences between
subtypes. As examples, subtypes within the alpha-HPV taxon
demonstrate how different the two measurements, complete
genome and L1 ORF comparisons are: HPV44 vs. HPV55 (CG:
6.2%, L1: 6.7%), HPV68 vs. ME180 (CG: 6.7%, L1: 7.9%), HPV34 vs.
Fig. 4. Phylogenetic trees showing representative types and variant lineages/sublineages. A maximum likelihood tree was constructed using RAxML HPC v7.2.8 (Stamatakis,
2006) inferred from the global alignment of complete genome nucleotide sequences using the program MUSCLE (Edgar, 2004) linearized at the ﬁrst ATG of the E1 ORF.
Representative genomes of each lineage and/or sublineage are listed in Table 1, with GenBank accession numbers. The bold part represents groupings of each type. The
length of dashed and solid lines represents distance between isolates, although the number of changes is different for these two lines; the scale is indicated in the upper left
corner of Figs. 2, 4 and 5; it is shown in the upper right corner of Fig. 3.
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HPV64 (CG: 4.7%, L1: 5.4%), HPV82 vs. AE2 (CG: 10.2%, L1: 7.7%),
HPV54 vs. AE9 (CG: 6.5%, L1: 4.6%), HPV52 lineage A vs. lineage D
(CG: 2.2%, L1: 2.2%), HPV58 lineage A vs. D (CG: 1.7%, L1: 2.2%).
Analyses of complete genome variants of HPV16
Since HPV16 is the most pathogenic and medically important
HPV type, we review the relationships amongst HPV16 variant
complete genomes. Prior phylogenetic analyses of HPV16 variants
(Chen et al., 2005; Ho et al., 1991; Yamada et al., 1997) identiﬁed
4 major intratypic variant lineages: European (E), Asian–American
(AA), African-1 (Af-1) and African-2 (Af-2). Fig. 1 depicts a whole-
genome phylogenetic tree (left panel, labeled “Complete genome
phylogeny”) and a plot of the pairwise differences between
all HPV16 complete-genome sequences (middle panel, labeled
“Complete genome”); a plot of the differences based on the L1
ORF nucleotide sequence is shown for comparison (right panel,
labeled “L1 ORF”). A global alignment of the 62 complete genomes
resulted in a matrix that is 7916 bp in length with a maximum of
10 insertions/deletions (indels) across all sequences (Smith et al.,
2011). All indels were within the highly variable non-coding
region between E5 and L2 (NCR, positions 4102–4236) of the
HPV16 genome. Comparison between all sequences identiﬁed a
total of 540 single nucleotide polymorphisms (SNPs) with any pair
of sequences having a maximum of 180 (2.3% of genome) differ-
ences. In addition to these genomes, Sabol et al. (2012) have
reported a 63 bp duplication within the E1 ORF (HPV16
(E1).1374_1436dup, also listed as E1-1374^63nt duplication) and
76 complete HPV16 genomes were sequenced from central China
(Sun et al., 2012), although the heterogeneity was limited to the A
lineages. The most striking observation about HPV16 variants is
the presence of genetic heterogeneity in what is called the “non-
European” lineages (i.e., lineages B/C/D) in contrast to the relative
homogeneity of the A (European) lineage. In addition to the
differences between the major variant lineages, there appears to
be sublineage structure; a feature notably well developed within
the D (AA) lineage. The tree demonstrates excellent support (i.e.,
all partitions have posterior probability of 1.0) for the placement of
all named lineages and sublineages. Sublineages refer to groups of
genome sequences with 0.5–1.0% differences between their gen-
omes that cluster in the phylogenetic tree (Chen et al., 2011).
Sublineages are indicated by brackets within distinct blocks of
similar color in Fig. 1. Taken together, these analyses suggest the
presence of evolutionarily ﬁxed sublineages at a deeper taxonomic
Fig. 5. Phylogenetic trees showing representative types and variant lineages/sublineages. A maximum likelihood tree was constructed using RAxML HPC v7.2.8 (Stamatakis,
2006) inferred from the global alignment of complete genome nucleotide sequences using the program MUSCLE (Edgar, 2004) linearized at the ﬁrst ATG of the E1 ORF.
Representative genomes of each lineage and/or sublineage are listed in Table 1, with GenBank accession numbers. The bold part represents groupings of each type. The
length of dashed and solid lines represents distance between isolates, although the number of changes is different for these two lines; the scale is indicated in the upper left
corner of Figs. 2, 4 and 5; it is shown in the upper right corner of Fig. 3.
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level than the 4 commonly recognized variant clades (i.e., E, Af-1,
Af-2 and AA; renamed A, B, C and D, respectively) (Chen et al.,
2005). Of note is the loss of clear resolution between lineages and
sublineages when only the L1 ORF nucleotide sequence is com-
pared (compare Fig. 1. middle panel to right-side panel). This
observation provides a concrete example for using complete HPV
genomes to deﬁne variant taxons, whereas the L1 ORF sequence is
sufﬁcient and robust for distinguishing HPV types (Bernard et al.,
2010).
Human alpha-PV species groups variant lineages
In this review, we present archetypal HPV genome isolates that
represent a speciﬁc variant lineage or sublineage as deﬁned above.
The originally deﬁned HPV type genome is always assigned to lineage
“A” or when sublineages are present, “A1”. It is appreciated that with
continued characterization of HPV complete genomes throughout the
world there will be additional isolates identiﬁed that deﬁne future
lineages and sublineages. The list of HPV genomes used in Figs. 2–5 is
provided in Table 1. These ﬁgures show the phylogenetic relation-
ships between representative isolates selected to provide a simpliﬁed
topology for nomenclature; the species groups are presented by
clinical importance based on association with cancers. Fig. 2 displays
types constituting species group alpha-9 (Chen et al., 2011; Smith
et al., 2011); HPV16, 52 and 58 each has 4 variant lineages and
multiple sublineages. HPV35 is the least heterogeneous. Fig. 3 shows
the topology of alpha-7 variant lineages and sublineages (Chen et al.,
2013). HPV68 contains 2 distantly related clades that are also referred
to as subtypes formed by isolates related to either the prototype
HPV68 (lineages A and B) or the variant ME180 (lineages
C/D/E/F). Relatively rare types, HPV85 and HPV97 have insufﬁcient
numbers of isolates detected to say with conﬁdence that there is little
or no viral heterogeneity. Fig. 4 shows the clade containing alpha-5
and alpha-6. HPV82 shows signiﬁcant diversity and like HPV68, has
2 clades also referred to as subtypes (i.e., HPV82 prototype, lineages
A/B; and AE, lineage C). Fig. 5 displays the topology of HPV isolates of
types from species groups: alpha-11 (HPV34 and HPV73), alpha-10
(HPV6 and HPV11), alpha-13 (HPV54) and alpha-3 (HPV61). HPV34
and HPV54 isolates show deep bifurcations that represent subtypes.
The characterization and nomenclature of HPV variants of HPV6 and
HPV11 were recently reviewed (Burk et al., 2011).
Conclusions
This review summarizes the current classiﬁcation of HPV
variants and provides a framework for developing a common
nomenclature as the papillomavirus ﬁelds embrace Next-Gen
sequencing. Massively parallel high-throughput sequencing is
anticipated to generate large amounts of data on papillomavirus
isolates, where it will be commonplace to obtain the complete
sequence in the matter of a few days. Implementation of the new
technologies will enable deﬁning the genotype-phenotype rela-
tionships between viral isolates and clinical outcomes, such as
cervix cancer. The classiﬁcation of variant genomes should be
based on a set of complete genomes, whereas the classiﬁcation of
HPV types is based on the L1 nucleotide sequences (Bernard et al.,
2010; de Villiers et al., 2004). The use of full genome sequences for
variant classiﬁcation is derived from the fact that isolates of the
same type are closely related and the full extent of the sequence
heterogeneity is best summed across the whole genome and
recently evolved variant genomes have changes that are not
always evenly distributed throughout the genome. Nevertheless,
to deﬁne distinct variant lineages, a nucleotide sequence differ-
ence of approximately 1.0% or more between two or more variants
of the same type is utilized. This value is derived from empiric data
on the distribution of differences between isolate genomes of the
same type from the alpha-9 species group (see Fig. S1). Similarly,
differences across the genome of 0.5%–1.0% are used to identify
sublineages. Each variant lineage has been classiﬁed and named
with an alphanumeric value. The prototype or reference sequence
(i.e., the cloned genome designated as the original type) is always
designated variant lineage A and/or sublineage A1 (Chen et al.,
2009, 2011, in press). Therefore, with classiﬁcation of variants
based on full genome sequences, it is thus possible to characterize
and name isolates by the use of lineage-speciﬁc diagnostic single
nucleotide polymorphisms (SNPs) or lineage-speciﬁc indels found
in short sequence reads in various predeﬁned regions of the
genome.
To facilitate the consistent numbering of nucleotide positions, a
summary table with key landmark nucleotide positions can be
used as a reference to name speciﬁc nucleotide variations within
human alpha-PV genomes. Nucleotide positions are based on the
reference sequence for each type. At some point in the past,
agreement arose within the PV community that the “A” of the ﬁrst
ATG in the E6 ORF should be designated position “1”. However, as
shown in the Table S1, few of the human alpha-PVs used this
criterion in naming position “1”. For instance, the sequence of
HPV16 deﬁnes position “1” based on an alignment with the ﬁrst
60 bp of HPV1a, HPV6b and BPV1 (Seedorf et al., 1985). Moreover,
there were sequencing errors in some reference clones that have
been corrected over time. For convenience, a table with both the
ﬁrst 8 nucleotides of the reference genome and the potential E6
start codon are provided. These 8 bp sequences can be used to
search the genome to locate landmarks of interest. We recom-
mend use of the E1 ORF ATG as a reasonably conserved site, at
least, in the human alpha-PVs for multiple sequence alignments.
Thus, the location of the E1 ATG established from the reference
sequence numbering and the 8 bp subsequent to the E1 ATG are
listed for quick identiﬁcation by searching. Recent discussions
amongst the Papillomavirus Working Group of the ICTV suggested
that nucleotide position “1” of new papillomavirus genomes
should be the ﬁrst nucleotide after the stop codon in the L1 ORF.
This recommendation is based on the fact that every papilloma-
virus has a unique L1 ORF stop codon, whereas there can be many
5′ ATGs in the E6 ORF that are not functional. As mentioned above,
for multiple sequence alignment we recommend the E1 ORF start
site, irrespective of nucleotide position.
The use of whole genomes for variant taxonomy provides HPV
researchers a simple mechanism to discuss the properties of HPV
variant lineages without having to describe sets of nucleotide
changes to deﬁne a group of HPV variants. This will be particularly
useful for future studies of the oncogenic HPV types. As discussed
above, there is growing evidence that variants of HPV16, HPV31,
HPV52 and HPV58 have different oncogenic properties (Berumen
et al., 2001; Chan et al., 2013; Chang et al., 2011; Cornet et al.,
2013b; Hildesheim et al., 2001; Schiffman et al., 2010; Smith et al.,
2011; Xi et al., 2012).
In summary, both the foundations of HPV variant research and
classiﬁcation and nomenclature for HPV variants based on the
sequences of complete genomes are reviewed. A summary of the
genomes for each lineage and sublineage are listed that can be
incorporated into analyses by investigators sequencing either the
full genome or subgenomic regions for variant classiﬁcations.
These variants should be useful for detailed studies addressing
the genetic basis of the pathogenesis of speciﬁc HPVs, viral–host
interactions and host evolution, amongst other applications and
scientiﬁc inquiries. The question then becomes to deﬁne the
speciﬁc nucleotides or combination of nucleotides that are asso-
ciated with speciﬁc pathologic consequences. It is anticipated that
multicenter studies and/or meta-analyses will be needed to
validate the nucleotide level of pathogenesis and provide insights
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into the molecular basis of HPV-associated disease. This review
provides the framework based on previous studies that should be
instrumental in the next stages of HPV genome research.
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